Collaborative Drug Discovery
| Company type | Private |
|---|---|
| Industry | Life Sciences, Informatics |
| Founded | 2004 |
| Headquarters | Burlingame, California |
| Products | CDD Vault, CDD Collaborate, CDD Public |
| Website | www.collaborativedrug.com |
Collaborative Drug Discovery (CDD) is a software company founded in 2004 as a spin-out of Eli Lilly by Barry Bunin, PhD. CDD offers a web-based database solution for managing drug discovery data, primarily around small molecules and associated bio-assay data.
Products
- CDD Vault - allows scientists[1] to maintain a private and secure collection of their data.
- CDD Collaborate - individual research groups can securely share subsets of data between Vaults.
- CDD Public - a free database for fostering open collaboration containing over 3 million molecules accessible to everyone in the drug discovery community at large.[2]
Collaborations
The capability for inter-group collaboration attracted attention from the Bill & Melinda Gates Foundation, who in 2008 awarded CDD with a two million dollar grant being used to support researchers combating Tuberculosis.[3]
In 2010, GlaxoSmithKline released 13,471 molecules screened for activity against Malaria to the public. These molecules and their associated screening data are available via CDD Public, as well in as the National Library of Medicine's PubChem and the European Bioinformatics Institute's ChEMBL database.[4] This data has served as the basis for several cheminformatics analyses[5][6][7]
In February 2011 CDD began participating in the collaborative MM4TB project led by Professor Stewart Cole[8] and including participants from AstraZeneca and Sanofi Aventis[9]
See also
References
- ^ CDD Community
- ^ CDD Product Page
- ^ Collaborative Drug Discovery Receives Grant to Support the Development of a Database to Accelerate Discovery of New Therapies Against Tuberculosis
- ^ New research identifies promising leads to follow in search for medicines to fight malaria Archived 2010-06-01 at the Wayback Machine
- ^ Sean Ekins and Antony John Williams, When Pharmaceutical Companies Publish Large Datasets: An Abundance of riches or fool’s gold? Drug Disc Today, 15; 812-815, 2010
- ^ Ekins S and Williams AJ, Meta-analysis of molecular property patterns and filtering of public datasets of antimalarial “hits” and drugs, MedChemComm, 1: 325-330, 2010
- ^ Ekins S, Kaneko T, Lipinski CA, Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Ernst S, Yang J, Goncharoff N, Hohman M and Bunin BA, Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis, Mol Biosyst, 6: 2316-2324, 2010
- ^ http://cole-lab.epfl.ch/
- ^ http://mm4tb.org/